Metabolic syndrome and prostate cancer: a review of complex interplay amongst various endocrine factors in the pathophysiology and progression of prostate cancer

Rhee, Handoo, Vela, Ian and Chung, Eric (2015) Metabolic syndrome and prostate cancer: a review of complex interplay amongst various endocrine factors in the pathophysiology and progression of prostate cancer. Hormones and Cancer, 7 2: 1-9. doi:10.1007/s12672-015-0238-x


Author Rhee, Handoo
Vela, Ian
Chung, Eric
Title Metabolic syndrome and prostate cancer: a review of complex interplay amongst various endocrine factors in the pathophysiology and progression of prostate cancer
Journal name Hormones and Cancer   Check publisher's open access policy
ISSN 1868-8500
1868-8497
Publication date 2015-11-06
Sub-type Article (original research)
DOI 10.1007/s12672-015-0238-x
Open Access Status Not Open Access
Volume 7
Issue 2
Start page 1
End page 9
Total pages 9
Place of publication New York, NY, United States
Publisher Springer New York
Language eng
Subject 2712 Endocrinology, Diabetes and Metabolism
2730 Oncology
1310 Endocrinology
2807 Endocrine and Autonomic Systems
1306 Cancer Research
Abstract The human prostate gland is an endocrine organ where dysregulation of various hormonal factors may play a pivotal role in the pathogenesis of prostate cancer. There is emerging epidemiological data to support the role of components of metabolic syndrome, namely, obesity, hypercholesterolaemia, diabetes and hyperinsulinaemia on the development and/or the progression of prostate cancer. Although the exact mechanisms behind the relationship between metabolic syndrome and prostate cancer remain largely unknown, various in vitro and animal experiments of metabolic syndrome models have been shown to promote survival, mitogenesis, metastasis and treatment resistance pathways, through various adaptive responses such as intracellular steroidogenesis and lipogenesis. Also, in a large proportion of men with metabolic syndrome, alteration in levels of hormones such as testosterone, leptin and adiponectin has been shown to contribute towards the aggression of prostate cancer. Whilst the exact bio-pathophysiological mechanisms between metabolic syndrome and prostate cancer are yet to be fully elucidated, medications that target specific components of metabolic syndrome have further provided evidence for the inter-relationship between metabolic syndrome, its components and prostate cancer. Emerging in vitro and molecular data is likely to bring us closer to utilizing this knowledge to target particular cancer survival pathways and improving outcomes for men with prostate cancer.
Q-Index Code CX
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Non HERDC
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 6 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 6 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 24 Nov 2015, 10:27:53 EST by System User on behalf of Scholarly Communication and Digitisation Service